• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug discovery today >Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant.
【24h】

Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant.

机译：脂联素正常化：利莫那班抗代谢综合征作用的线索。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Obesity, currently associated with metabolic syndrome is characterized by an excessive fat storage in different organs, in particular adipose tissue, inducing the loss of its structural and functional integrity. Being aware of the importance of adipose tissue endocrine function and the key role of adipocytokines, such as adiponectin, in obesity and metabolic syndrome drives the necessity to develop new drugs that can exert a specific action on adipose tissue and on adiponectin levels. Rimonabant, an antiobesity drug, presents a dual effect by decreasing food intake and importantly increasing adiponectin. This review focuses on the key role of adiponectin regulation in the success of rimonabant and suggests that this adipohormone may be considered as a therapeutic target to design innovative and promising antiobesity and anti-metabolic syndrome drugs.
机译：当前与代谢综合征相关的肥胖症的特征在于在不同器官，特别是脂肪组织中过多的脂肪储存，导致其结构和功能完整性的丧失。意识到脂肪组织内分泌功能的重要性以及脂肪细胞因子（如脂联素）在肥胖和代谢综合征中的关键作用，驱使开发能够对脂肪组织和脂联素水平发挥特定作用的新药物的必要性。利莫那班是一种抗肥胖药，它通过减少食物摄入量和重要地增加脂联素发挥双重作用。这篇综述着重于脂联素调节在利莫那班成功中的关键作用，并建议该脂激素可被认为是设计创新和有希望的抗肥胖和抗代谢综合征药物的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号